Paper Details

  1. Home
  2. Paper Details

Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial.

Author: BallH, BlessingJ A, LentzS S, MarkmanM, MooreD

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

This Phase II trial found that altretamine had limited activity in platinum-refractory ovarian cancer. The major side effect was emesis.
Paper Details　
Original Abstract of the Article :
OBJECTIVES: In an effort to critically examine the antitumor activity of altretamine (hexamethylmelamine) as salvage therapy of platinum-refractory ovarian cancer, the Gynecologic Oncology Group initiated a Phase II trial of the agent administered in this clinical setting. METHODS: Altretamine was ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1006/gyno.1998.5016

データ提供：米国国立医学図書館（NLM）

Exploring Altretamine’s Effectiveness in Platinum-Resistant Ovarian Cancer

The field of oncology is always seeking innovative ways to combat cancer, especially in challenging cases like platinum-resistant ovarian cancer. This research delves into the effectiveness of altretamine, a drug often used as salvage therapy for this type of cancer. The study used a phase II trial to investigate the antitumor activity of altretamine in patients who had already received platinum-based treatments. The researchers administered altretamine at a specific dose and monitored patients for response and side effects.

Limited Activity in Platinum-Resistant Ovarian Cancer

The results indicated that altretamine demonstrated only limited activity in patients with platinum-resistant ovarian cancer. The objective response rate, which measures the effectiveness of the treatment in shrinking or eliminating tumors, was only 10%. This means that only 10% of the patients in the study experienced a positive response to the treatment.

Navigating Treatment Options for Ovarian Cancer

The findings suggest that altretamine might not be a viable treatment option for all patients with platinum-resistant ovarian cancer. This highlights the need for ongoing research to find more effective treatments for this aggressive form of the disease. Patients should consult with their oncologists to discuss the most appropriate treatment options based on their individual circumstances.

Dr.Camel's Conclusion

This study reminds us that the fight against cancer requires continuous exploration and innovation. While altretamine may not be the ultimate answer for all patients with platinum-resistant ovarian cancer, it’s a step forward in understanding the nuances of this complex disease. Like a camel traversing the vast desert, we continue our search for solutions, driven by our unwavering hope and commitment to improving patient outcomes.

Date :
  1. Date Completed 1998-07-15
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

9648592

DOI: Digital Object Identifier

10.1006/gyno.1998.5016

Related Literature

Article Analysis
・Side Effects of altretamine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.